Fate Therapeutics (FATE) News Today → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Free FATE Stock Alerts $3.80 -0.07 (-1.81%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineStruggling retail chain shares Chapter 11 bankruptcy fatethestreet.com - April 27 at 9:02 AMGrandmother gets new lease on life from heart pump, pig kidneymsn.com - April 26 at 11:01 PMBiden campaign says it will keep using TikTok - despite president signing law that could ban appmsn.com - April 26 at 7:58 AMOrlando police fulfill 4-year-old boy's dream of being an officeryahoo.com - April 26 at 7:58 AMFederated Hermes Inc. Sells 601,672 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)marketbeat.com - April 25 at 5:41 AMFate Therapeutics (NASDAQ:FATE) Given "Neutral" Rating at Wedbushamericanbankingnews.com - April 24 at 4:44 AMReviewing Immatics (NASDAQ:IMTX) & Fate Therapeutics (NASDAQ:FATE)americanbankingnews.com - April 24 at 1:48 AMOur Reporter on the Fate of a Gazan University Classnytimes.com - April 23 at 7:03 PMFate Therapeutics' (FATE) "Neutral" Rating Reaffirmed at Wedbushmarketbeat.com - April 23 at 1:49 PMFate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meetingglobenewswire.com - April 22 at 4:30 PMFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analystsamericanbankingnews.com - April 22 at 2:46 AMFate Therapeutics (NASDAQ:FATE) Stock Price Down 5.4%americanbankingnews.com - April 21 at 5:34 AMFate Therapeutics (NASDAQ:FATE) Shares Down 5.4% marketbeat.com - April 19 at 2:56 PMFate Therapeutics files to sell 3.64M shares for holdersmsn.com - April 18 at 7:46 PMFate Therapeutics (NASDAQ:FATE) Shares Gap Up to $5.38marketbeat.com - April 17 at 11:37 AMFate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interestmarketbeat.com - April 15 at 7:40 PMFate Therapeutics, Inc. (NASDAQ:FATE) Position Trimmed by Vanguard Group Inc.marketbeat.com - April 14 at 4:16 AMFate Therapeutics' (FATE) Hold Rating Reiterated at Needham & Company LLCmarketbeat.com - April 11 at 8:31 AMA promising target for new RNA therapeutics now accessiblemsn.com - April 10 at 6:02 PMFate Therapeutics (NASDAQ:FATE) Stock Price Down 2.5%marketbeat.com - April 8 at 11:59 AMAssenagon Asset Management S.A. Sells 217,640 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)marketbeat.com - April 8 at 4:20 AMTerminator: Edward Furlong Addresses John Connor’s Death In Dark Fateyahoo.com - April 3 at 8:27 PMFate Therapeutics (NASDAQ:FATE) Stock Price Up 7.1%marketbeat.com - April 3 at 4:50 PM‘It Was A Mixed Feeling’: Terminator’s Edward Furlong Opens Up About Shooting His Controversial John Connor Cameo In Dark Fateuk.movies.yahoo.com - April 3 at 10:26 AMFate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 3 at 10:26 AMFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 2 at 4:01 PMX Factor star Lucy Spraggan says Simon Cowell will walk her down the aisle at weddingnz.news.yahoo.com - March 31 at 8:16 PMI visited Mother Mercy to learn more about their new Twist of Fate experience - and tried it out for myselfmsn.com - March 31 at 8:16 PMCautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concernsmarkets.businessinsider.com - March 29 at 3:33 AMFate Therapeutics (NASDAQ:FATE) Price Target Raised to $6.00 at Bank of Americamarketbeat.com - March 28 at 2:35 PMFate Therapeutics (NASDAQ:FATE) Shares Up 5.1%marketbeat.com - March 25 at 5:33 PMFate Therapeutics Stock (NASDAQ:FATE), Quotes and News Summarybenzinga.com - March 24 at 8:37 AMFate Therapeutics (NASDAQ:FATE) Shares Down 7% marketbeat.com - March 22 at 5:05 PMEvaluating Fate Therapeutics: Insights From 5 Financial Analystsmarkets.businessinsider.com - March 19 at 5:48 PMFate Therapeutics Prices $100 Mln Of Public Offering, Concurrent Private Placementmarkets.businessinsider.com - March 19 at 12:47 PMFate Therapeutics announces pricing of $100M underwritten offering and concurrent private placementmsn.com - March 19 at 12:47 PMFate Therapeutics (NASDAQ:FATE) Shares Gap Down to $7.04marketbeat.com - March 19 at 11:53 AMFate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placementglobenewswire.com - March 19 at 8:44 AMFate Therapeutics' (FATE) "Neutral" Rating Reiterated at HC Wainwrightmarketbeat.com - March 19 at 8:34 AMFATE Apr 2024 5.000 putfinance.yahoo.com - March 16 at 3:33 PMFATE Aug 2024 5.000 putfinance.yahoo.com - March 16 at 10:33 AMFATE Apr 2024 7.500 putfinance.yahoo.com - March 16 at 10:33 AMFate Therapeutics (NASDAQ:FATE) Stock Price Up 4.7%marketbeat.com - March 15 at 1:47 PMFate Therapeutics (NASDAQ:FATE) Trading Down 6.9%marketbeat.com - March 14 at 12:47 PMVindictus: Defying Fate is worth trying for free even if you never played the MMOmsn.com - March 14 at 7:59 AMFATE Mar 2024 10.000 putfinance.yahoo.com - March 7 at 10:41 AMFate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - March 6 at 11:29 PMFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 5 at 4:01 PMAlgert Global LLC Has $195,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)marketbeat.com - March 4 at 6:01 AMQ1 2024 Earnings Forecast for Fate Therapeutics, Inc. Issued By Wedbush (NASDAQ:FATE)marketbeat.com - March 2 at 2:29 AM Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address How a $0.25 cent option contract makes my top traders feel (Ad)If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently… Click now to see for yourself what $0.25 Cent Trades is all about FATE Media Mentions By Week FATE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.130.32▲Average Medical News Sentiment FATE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼143▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alector News Exscientia News Valneva News C4 Therapeutics News Taysha Gene Therapies News Humacyte News Allogene Therapeutics News Prime Medicine News ProKidney News Editas Medicine News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryWhy Big Pharma is Investing Billions in This BiotechBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
